In family studies, cosegregation of the mutation with the disease could be demonstrated for five mutations; for two
missense mutations, this was not possible due to limited family data. All seven mutations were the only abnormalities identified in the respective index patients and were absent in 44 to 62 normal individuals. Therefore, they most likely represent the causal gene defects. For five mutations, analysis of ectopic RNA could be performed. Mutant transcripts were present in the case of the frame shift and three of the missense mutations, while no mutant RNA could be detected in the case of the stop codon. 0 1995 by The American Society of Hematology.
heterozygous protein S-deficient individuals. All test systems show a considerable overlap between protein S plasma levels found in normal individuals and in deficient heterozygotes. Especially in the case of oral anticoagulation, the diagnostic uncertainty with conventional test systems is very high. Only a genetic approach that identifies the causative mutations in protein S-deficient individuals can bypass these diagnostic pitfalls.
Protein S is encoded by the active PROS 1 gene on chromosome 3, and an inactive pseudogene, PROS 2, also exists on chromosome 3.lh.I7 PROS 2, which is not transcribed, shows a homology of 97% with PROS 1, but differs by the absence of exon 1 and the presence of stop codons within the gene."-'" It can be expected that mutations causing protein S defects will be located within the PROS 1 gene. To date, two major deletions2'.'' and 21 point mutations".23-2h in the PROS 1 gene have been reported as putatively causal mutations in protein S deficiency. Analysis of PROS 1 mRNA was shown to be unsatisfactory to search for mutations in protein S-deficient families, as gene defects interfering with mRNA synthesis and/or processing remained undetected. ' In contrast, the screening of the 15 individual exons and the exonhntron boundaries of the PROS 1 gene allows identification of all genomic mutations in the coding region and the splice junction sites.
Using this approach, we identified mutations in 9 of I O individuals with protein S deficiency. The nine individuals shared seven different mutations; two mutations occurred in two subjects each. Interestingly, one of these mutations (a splice site mutation at position +5 of the donor splice site of intron 10) has previously been reported in two unrelated, protein S-deficient patients of Dutch origin.27 Whether this splice site mutation represents a mutational hot spot remains to be determined.
PATIENTS AND METHODS
Patients. The protein S-deficient patients selected for the study were identified during the investigation of individuals with a history of objectively documented thrombosis and/or pulmonary embolism.
Individuals who had developed thrombosis early in life (before 45 years of age) or who had a positive family history (around 30% of all investigated patients) were screened for protein S deficiency by determination of free protein S antigen (Table I) patients, a panel of 10 probands was selected for the molecular biologic investigations. All index patients had a positive family history for thromboembolism. Except patient 9 4 2 , who is an Argentinean of European origin, and patient 5-I/1, who is German, all index patients are Austrians.
Protein S determination and diagnostic criteria. Free and total protein S antigen were measured by a commercial enzyme-linked immunosorbent assay (Boehringer-Mannheim, Mannheim, Germany). For determination of free protein S, bound protein S was precipitated with polyethyleneglycol (PEG 8000; 3.75%) according to the method of Comp et al,'* and free protein S was determined in the supernatant. The amount of free protein S in PEG-precipitated pooled normal plasma was defined as 100%.
The lower limit of the normal range for free protein S was 6 4 % in patients without oral anticoagulant (OAC) treatment and 19% for patients on OAC. For total protein S, the lower limit of the normal range was 65% in patients without and 35% in patients with OAC treatment.
The diagnosis of hereditary protein S deficiency type I was considered as established when decreased free and total protein S values were repeatedly found in a proband and when protein S deficiency was detected in at least one further relative, irrespective of the thrombotic history in that individual. Using the above-mentioned cut-off limits, in three families (families 3, 7, and 9). individuals with decreased free but normal total protein S values (patients 3-U1, 7-I/1, and 9 4 2 ) were found in addition to the typical type I-deficient patients. Families in which all deficient family members had type 111 deficiency were not included in our study.
Genomic DNA analyses. Genomic DNA was extracted from EDTA or citrated blood samples * Primer for cDNA amplification. § Primer for sequencing.
chain reaction (PCR)" products were sequenced directly by the method of Sanger?' Primers chosen for PCR amplification (of exons, including exon-intron boundaries; Table 2 ) were constructed from genomic sequences using differences between the PROS 1 and the PROS 2 genes."-" They were positioned such that the 3' end of at least one of the two primers was only complementary to the PROS I gene. As no sequence differences between PROS 1 and PROS 2 were known for exon 3, we amplified this exon and large parts of boundering introns with primers presumed to be common to both genes. The PCR product (340 bp for PROS 1) was sequenced, and the differences found between the known PROS 1 gene sequence and the pseudogene sequence were used to design PROS l-specific primers PS-414 and P S 4 5 . All amplification products included at least 10 nucleotides of 5' and 3' flanking intron sequences, except for only five nucleotides at the 5' splice junction of exon 2 and only nine nucleotides at the 3' splice junction of exon 7. Amplifications were performed in a DNA Thermal Cycler (Perkin-Elmer Cetus, Norwalk, CT) using Taq-DNA-polymerase (Roche Molecular Systems, Inc. Branchburg, NJ Abbreviations: -, unknown; ND, not done. cycles with an annealing temperature of 60°C were followed by 30 cycles at 50°C. Because the pseudogene sequence at the 5' end of intron 14 was not available, and intron 13 sequences were not appropriate to choose a PROS 1 gene-specific primer, 0.5-pL PCR products (containing parts of intron 12, exon 13, intron 13, exon 14, and parts of intron 14) obtained with primers PS-24s and PS-EXIV-2 were submitted to 12 cycles of seminested amplification using primers PS-EXIV-1 Purification of PCR products was performed on low melting point agarose. Gel slices were melted (70Q shock-frozen (-7O"C), and centrifuged (12,OOOg) after thawing.29 Two to five microliters of the supernatant and 10 to 30 pmol primer were used for sequencing with Sequenase v 2.0 (US Biochemical, Cleveland, OH) and [a-'5S]-deoxyadenosine triphosphate (dATP; Amersham, Amersham, UK).
Index patients were sequenced in all exons. Any detected mutation was confirmed by analysis of the respective exon in key relatives. cDNA preparation. Total RNA was isolated from 2 mL whole blood using a commercial kit (Fastube RNA Extraction System, ViennaLab, Vienna, Austria), based on a guanidinium phenol and PS-EXIV-2. method.30 Half the RNA obtained by one isolation was used for random-hexamer primed cDNA synthesis with M-MLV reverse transcriptase."
Preparation of PCR products for digestion with Acc l, Bpm l, BstXI, and Eae I. Primers (Table 2) ... amplification product, and the digests were incubated at 37°C (Acc I, Eae I, Bpm I) and 45°C (BsrXI) for 3 to 15 hours. The cleavage products were analyzed on precast 6% polyacrylamide gels (Novex, San Diego, CA), followed by staining with ethidium bromide.
Heteroduplex analysis of mut-I. Genomic DNA was amplified with primers PS-19/1 and PS-P1B. PCR products were separated at constant voltage (100 V) on precast 6% polyacrylamide gels.
RESULTS
For all 10 index patients, heterozygous hereditary protein S deficiency type I was verified on the basis of their free and total protein S values (Table l) , as well as their family histories of protein S deficiency. Except patient 2 4 3 , who experienced only one thrombotic event, all index patients had recurrent thrombosis.
Results of DNA analysis. In nine index patients, seven different mutations (mut-l through mut-7; Table 3 , Fig  l ) were identified by direct sequence analysis of all exons and splice regions of the PROS 1 gene. For five mutations (mut-1, -2, -3, -5, -7), cosegregation with the disease could be demonstrated. For mut-4 family 7 and mut-6 family 9, this was not possible, because pedigrees were incomplete (Fig  2) . All seven mutations were absent in 44 to 62 normal individuals.
In addition to the mutations, the exonic G/A dimorphism in codon 62632,33 and two unpublished dimorphisms, one exonic and one intronic, were identified in some patients.
These two dimorphisms were also found in 30 healthy control individuals with an allelic frequency of more than 10% (data not shown). No other genetic alterations were seen in the tested sequences. Among the seven identified mutations, three have a major impact on the expected gene product: a 2-bp deletion. a splice site mutation, and a nonsense mutation.
The 2-bp deletion (mut-l) at cDNA positions 2166 and 2167 (cDNA numbering according to Hoskins et al") leads to a changed reading frame. The mutation was found in two unrelated index patients (1-1V4 and 4-VI). Both of them had experienced recurrent thrombosis. For patient 1 -W4, three protein S-deficient relatives (two of them symptomatic) as well as four relatives with normal protein S values were tested for the mutation by heteroduplex analysis. All protein S-deficient family members were found to carry the deletion, while it was absent in all unaffected relatives ( Table 1 ) and in 44 normal controls.
The mutation in the donor splice site of intron 10 (mut-2) presumably affects splicing."
It was observed in two unrelated index patients (2-1/3 and 3 4 1 ) who both had experienced thrombosis. By direct sequencing of PCR products (PS-21/1 and PS-22/1), this mutation could be demonstrated in all protein S-deficient relatives of both index patients, but was not present in the unaffected relatives or in a group of 45 normal control individuals.
The nonsense mutation in family I O (mut-7) converts arginine-410 into a stop codon. Direct sequencing demonstrated the presence of this mutation in all three protein S-deficient members of this family, of whom two had experienced thrombosis. In two relatives with normal protein S values, as well as in 44 unrelated normals, the mutation was absent. Interestingly, the same mutation is found in the protein S pseudogene (PROS 2).
Three missense mutations were identified in exon 14 of index patients 6-V1, 7-1/1, and 8-IIVI: mut-3 (Ala 575 to Pro), mut-4 (Leu 543 to Gln), and mut-5 (Leu 51 1 to Ser), respectively. All three missense mutations were present in the protein S-deficient family members but absent in relatives with normal protein S levels, and in 46, 52, and 52 normal individuals. Another missense mutation (mut-6) was identified in exon 10. This mutation changes Leu 310 to Pro, and was identified in two protein S-deficient brothers. It was absent in 62 normal individuals.
Results of RNA analysis. RNA isolated from peripheral blood of six patients was available for RNA studies. Four individuals (patients LW4, 4-Y1, 7 4 1 , and 8-IIV2) were heterozygous for the codon 626 G/A dimorphism, which affects a Bst X1 restriction site. In all four patients, cDNA amplification (PS-18/3 and PS-PlB) and digestion with Bst XI proved the presence of mutant and wild type RNA ( Fig  3A) . Haplotypes of affected alleles (obtained from pedigree analysis; data not shown) were G in families I and 4 and A in family 8. Visual inspection of the Polaroid photographs indicated higher concentrations of normal transcripts in patients l -11/4, 4-1/1, and 8-111/2. The haplotype of the mut-4 allele (family 7) could not be determined. In families 6 and 10 no individual was heterozygous for the codon 626 dimorphism. Because mut-3 causes the loss of an Eue I site and use only. mut-7, the loss of an Acc I site, restriction enzyme cleavage mented family history of protein S deficiency and thrombocould be used for the detection of mutant transcripts. After embolism. Seven different, putatively causal mutations were digestion with &e 1. uncleaved (876 bp) mutant and cleaved identified in 9 of 10 unrelated patients with hereditary protein (803 bp + 73 bp) wild type Sequences could be Seen in equal S deficiency. Major evidence for pathogenicity of these muamounts in the cDNA PCR product of patient 6-1/1 (Fig 3R) .
tations was their at-,sence in a group of normal controls (44 Cleavage or the respective cDNA PCR product (ps-I0/1 and to 62 individuals). ,411 mutations were also the only genetic PS-15-AS) from patient 10-1/2 with Act* l resu1ted in the abnormalities found in the investigated sequences of the progeneration of three bands with 412, 322, and 73 bp, representing wild type. No mutant transcript (expected bands at 485, 322 bp) was present (Fig 3C) . tein S-deficient individuals. Pedigree analysis was performed to distinguish these putatively causal mutations from DNA alterations not linked to protein S deficiency. For five mutations (mut-l. -2. -3. -5. and -7). the transmission within We established a useful protocol for the detection of gene sufficiently large families could be studied, and all five muta-DISCUSSION alterations in the PROS I gene in patients with a well-docu-tions cosegregated with the disease.
use only.
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The causality of the 2-bp deletion (mut-l) and the splice site mutation (mut-2) for protein S deficiency is supported by the occurrence of each mutation in two different, reportedly unrelated protein S-deficient families. Mut-2 was also identified in two of eight genetically investigated Dutch families with protein S deficiency." Whether this high frequency of mut-2 is due to the presence of a mutational hot spot remains to be determined.
The deletion of two adenines in codon 633 leads to the use of a new reading frame. The normal stop codon is skipped and a new stop codon 62 bases downstream comes in frame. The new sequence codes for 23 amino acids (QFLRHLFSAYNTFSLCVIILMFQ), including one cysteine, instead of only three amino acids (KNS) in individuals with normal protein S. As we could demonstrate transcription of mutant RNA, it is feasible that an aberrant protein is translated from this mutant RNA. The secretion of this protein would presumably be impaired due to interference with proper folding of one unpaired cysteine contained in the extra amino acid ~equence.'~~'~ Mutation mut-7 introduces a stop codon at the beginning of exon 12. Aberrant RNA is absent from ectopic transcripts in blood cells, and a truncated gene product in protein S synthesizing cells is unlikely.
Mutations mut-3 and mut-6 lead to the replacement of alanine-575 and leucine-3 10, respectively, by proline, which is known to interrupt the formation of any regular repeating structure. This could destabilize the conformation of protein S, making it vulnerable against degradation or retaining it from secretion."^" In a secondary structure model of protein S reported by Schmidel et all8 and calculated according to Chou and Fasman," proline-575 would lie in the region of a conversion of an a-helical into an irregular structure. Using the same model, proline-310 would disrupt a region of predicted p sheet structure and would, therefore, significantly impair the secondary structure.
Common to mut-4 and mut-5 is the change of leucine, a hydrophobic amino acid, into a polar amino acid: glutamine and serine, respectively. Leucine-543 (mut-4) is conserved in human, bovine,38 mouse,'' and rabbit4' protein S amino acid sequences. At position S1 1 (mut-S), all three nonhuman protein S sequences carry hydrophobic valine. Apparently, there is a demand for branched, aliphatic amino acids at position 543 and 5 1 1, as evidenced by the high conservation during evolution.
We could detect transcripts of the mutant allele in four of five different mutations when we analyzed cDNA generated from total RNA. No mutant transcript was found in the case of the stop codon. In the presence of the 2-bp deletion and the Leu-51 1 to Ser mutation, the concentration of mutant transcripts was lower than of wild type. Our results indicate that RNA analysis is not suitable for the detection of all mutations in the PROS 1 gene, such as Arg-410 to stop, and only DNA analysis is adequate.6
Interestingly, a high frequency of missense mutations (four of seven) was observed. Similar results have already been reported for gene alterations in hereditary protein C deficiency, in which more than half of all mutations are also missense mutations.4'
The identification of mutations in the PROS I gene not only contributes to the understanding of pathogenic mutations, but helps to clarify diagnostic uncertainties. It is well known that an overlap of free and total protein S values exists in deficient patients and normal controls. We observed slightly reduced free and normal total protein S values in individual 4-1UI (daughter of a protein S-deficient father), and her protein S deficiency status was unclear. Gene analysis could redress uncertainties by demonstrating absence of the PROS 1 gene mutation in this individual.
Thus, our study also shows the value of gene analysis for diagnostic applications.
